drugset / Trial / NCT02191254

Efficacy and Tolerability of Antistax® in Male and Female Patients Suffering From Chronic Venous Insufficiency

NCT02191254 ↗

Phase 3 Completed 245 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to assess the efficacy and tolerability of Antistax® film-coated tablets in patients with chronic venous insufficiency (CVI, Clinical condition, Etiology, Anatomic location, Pathophysiology (CEAP) Classification: Clinical Class 3, or 4a)

Timeline

Start
2004-04
Primary completion
2004-10
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Antistax Unknown 360 mg Oral

Indications